Depressive DisordersPersonality & Trait FactorsInterpersonal Functioning & Social ConnectednessAyahuasca

Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study

In a prospective naturalistic study of 54 retreat attendees, participants showed increased aesthetic experience at one week and one month after an ayahuasca ceremony compared with baseline. These increases were not predicted by acute drug effects (mystical-type experiences, awe, ego dissolution), though the open‑label design limits causal conclusions.

Authors

  • Alan Davis
  • Joshua Woolley
  • Jordan Aday

Published

Journal of Humanistic Psychology
individual Study

Abstract

Psychedelic drugs are currently being investigated for their potential to facilitate a variety of long-lasting psychological changes. One area that has yet to be systematically investigated in psychedelic research, however, regards changes in aesthetic experience (i.e., one’s attitudes, perceptions, and expression of art). This is surprising given the wealth of anecdotes directly noting increased appreciation of aesthetic experiences after psychedelic use and that psychedelics have facilitated their own distinctive aesthetic (i.e., “psychedelic art”). To address this gap in the literature, participants in the current study ( N = 54) completed a validated and multifaceted measure of aesthetic experience 1-week before, 1-week after, and 1-month after attending an ayahuasca retreat. We found that compared with baseline, participants exhibited increased levels of aesthetic experience at both the 1-week and 1-month follow-ups. Contrary to our hypotheses, measures of acute drug effects (e.g., mystical-type experiences, awe, and ego dissolution) did not predict changes in aesthetic experience. Although the study was limited by an open-label design, the results support anecdotal reports noting changes in aesthetic experience after psychedelic use. Further research is needed to address limitations related to the study design as well as to identify predictors and mechanisms of changes in aesthetic experience following psychedelic use.

Unlocked with Blossom Pro

Research Summary of 'Increases in Aesthetic Experience Following Ayahuasca Use: A Prospective, Naturalistic Study'

Editorial

βBlossom's Take

This paper is useful because it takes a frequently mentioned after-effect of ayahuasca, heightened aesthetic appreciation, and measures it prospectively rather than leaving it as anecdote. The open-label retreat design limits causal claims, but the fact that the change persists for a month makes aesthetic experience a plausible outcome domain for later work.

Introduction

Classic serotonergic psychedelic drugs such as ayahuasca are being revisited by researchers because of their potential to produce lasting psychological and personality changes when used in controlled contexts alongside therapeutic support. While prior work has documented clinical and prosocial outcomes (for example, reductions in depression and increases in openness to experience), comparatively little systematic research has focused on aesthetic experience despite strong anecdotal reports and the prominent role of music, lighting and visual art in psychedelic settings. Aday and colleagues designed a prospective, naturalistic study to address this gap by administering a validated, multifaceted measure of aesthetic experience before and after participation in an ayahuasca retreat. The investigators also measured acute subjective effects during participants' most intense ayahuasca session—mystical-type experience (MEQ30), awe (AWE-S), and ego dissolution (EDI)—to test whether these acute phenomena predicted longer-term changes in aesthetic engagement.

Methods

Participants were recruited from Soltara Healing Centre, an ayahuasca retreat in Puntarenas Province, Costa Rica, and had to be at least 18 years old and clear a medical intake that screened out contraindicated psychiatric disorders (e.g., schizophrenia, bipolar disorder), certain medications (e.g., lithium), and cardiac conditions. Recruitment occurred via email after retreat registration and a website posting; participants could enter a prize drawing for completing all survey sessions. The study used an open-label, within-subjects design with three assessment points: one week before the retreat (T1, baseline), one week after the retreat (T2), and one month after the retreat (T3). Institutional Review Board approval and informed consent were obtained. Measures included demographic variables collected at T1 (the extracted text does not fully report all demographic items), the Aesthetic Experience Questionnaire (AEQ; a multifaceted measure of aesthetic experience) at each time point, and at T2 the MEQ30 (mystical-type experience scale), AWE-S (awe scale), and EDI (Ego-Dissolution Inventory). The retreat context and dosing were naturalistic: participants stayed 5–12 nights, attended between 2 and 7 ayahuasca sessions (M = 3.67, SD = 0.85), and ceremonies were group-based (up to 21 people) led by Shipibo curanderos. Typical dosing reported in the extraction was approximately one ounce for first ceremonies and two ounces thereafter, with sessions lasting roughly five hours. For analysis, the researchers computed change scores on the AEQ (AEQΔ1 = T2 − T1; AEQΔ2 = T3 − T1) and ran a 3 × 6 repeated-measures analysis of variance (ANOVA) with Time (T1, T2, T3) and AEQ Facet (perceptual, emotional, cultural, understanding, flow—proximal conditions, flow experience) to test for overall and facet-specific changes. They then tested two-way Pearson correlations between MEQ30, AWE-S, EDI scores and the AEQ change scores to evaluate whether acute drug effects predicted longer-term change. The extracted methods do not report an intention-to-treat strategy beyond participant inclusion/exclusion described below.

Results

The analytic sample comprised 54 participants after attrition and removal of one respondent who did not partake in any ceremonies (initial baseline N = 77; T2 N = 65; T3 N = 55). The final sample had a mean age of 41.17 (SD = 11.24), 24 female participants, was highly educated (88.9% with a college degree or higher), and predominantly non-Hispanic white (74.1%). Reported household income was relatively high for many participants (38.9% > $125,000/year). Prior psychedelic experience varied: 18.5% reported never having used a psychedelic, 29.6% reported 1–5 prior uses, and the remaining participants reported higher ranges up to >100 uses. Primary outcome results show a significant main effect of Time on AEQ total scores (F(1, 53) = 15.98, p < .001, eta_p^2 = 0.23), with AEQ scores at both one-week (T2) and one-month (T3) follow-ups significantly higher than baseline (T1). This indicates an increase in overall aesthetic experience that persisted for at least one month. The main effect of Facet was also significant (F(1, 53) = 141.40, p < .001, eta_p^2 = 0.73), while the Time × Facet interaction was not significant (F(1, 53) = 0.89, p > .05, eta_p^2 = 0.02). Pairwise comparisons indicated that every AEQ facet increased at T2 and T3 compared to baseline except the perceptual facet at T2, which did not reach significance (p = .103). Analyses testing predictors of change found that MEQ30, AWE-S, and EDI scores from participants' most intense ayahuasca session were not significantly correlated with one-week or one-month changes in AEQ total scores; correlation coefficients were described as generally trending in the expected direction but non-significant. The number of ayahuasca sessions attended was not related to AEQ change (r = −.01, p > .05).

Discussion

Aday and colleagues interpret the findings as providing empirical support for widespread anecdotal claims that psychedelic experiences can increase engagement with and appreciation of aesthetic experiences. The observed increases in AEQ scores at one week and one month post-retreat suggest that changes in aesthetic experience following ayahuasca can be sustained for at least a month. Contrary to the authors' hypotheses, acute subjective effects commonly linked to longer-term outcomes—mystical-type experience (MEQ30), awe (AWE-S), and ego dissolution (EDI)—did not significantly predict changes in aesthetic experience. The investigators note that prior literature has found those acute measures to forecast various persisting psychological changes, and they raise the possibility that other mechanisms (for example, acute alterations in visual processing or changes in trait openness to experience) might better account for the observed shifts in aesthetic engagement. The paper cites earlier research linking openness with deeper aesthetic responses and the known impact of psychedelics on openness as a plausible pathway. Several limitations acknowledged by the authors temper the conclusions. The naturalistic, open-label design lacked a placebo or active-control condition and therefore cannot rule out expectancy effects or non-pharmacological contributors to change. The retreat context included amenities (e.g., hiking, yoga, social interactions) that may have influenced outcomes, and dosing as well as number of ceremonies varied across participants; however, number of sessions was not associated with AEQ change. The authors also note broader methodological challenges in psychedelic research regarding blinding, and they argue that open-label, ecologically valid designs have advantages even as better-controlled designs continue to be developed. Strengths of the study include adequate power for the planned analyses, strong participant retention, multiple post-acute follow-ups, ecological validity afforded by a real-world retreat setting, and use of a validated, multifaceted measure of aesthetic experience. The researchers conclude that their findings validate anecdotal reports of increased aesthetic engagement after ayahuasca use and provide groundwork for future studies that should address blinding, appropriate control groups, the role of setting, and the durability of effects over longer follow-up periods.

View full paper sections

RESULTS

A 3 × 6 repeated-measures analysis of variance (ANOVA) was run on AEQ scores with three levels of Time (T1, T2, and T3) and six levels of Facet (perceptual, emotional, cultural, understanding, flow -proximal conditions, flow experience). Scores on the MEQ30, AWE-S, and EDI were correlated with one-week and one-month changes (∆) in AEQ total scores with two-way Pearson correlations. One-week change scores (AEQ∆ 1 ) were calculated by subtracting baseline (T1) AEQ total scores from one-week post-retreat (T2) AEQ total scores (e.g., T2-T1 = AEQ∆ 1 ). One-month change scores (AEQ∆ 2 ) were calculated by subtracting baseline (T1) AEQ total scores from one-month post-retreat (T3) AEQ total scores (e.g., T3-T1 = AEQ∆ 2 ).

CONCLUSION

Alterations in one's appreciation of, and engagement with, aesthetic experiences after psychedelic use has long been reported, but systematic study with validated measures has been lacking. In this study, we measured participants' levels of aesthetic experience one week before, one week after, and one month following attending an ayahuasca retreat. We found that aesthetic experience increased at both follow-ups compared to baseline. Contrary to our hypotheses, the extent to which participants endorsed mystical-type experiences, feelings of awe, and ego dissolution during their most intense ayahuasca session was not related to changes in aesthetic experience. Generally, our findings are in line with anecdotes about individuals becoming more engaged and interested in aesthetic experiences after psychedelic use and expand upon earlier studies that used less refined measures of aesthetic experience (e.g.,. Given that openness to experience has been associated with enhanced aesthetic experience, and that psychedelics have been shown to increase openness across a number of studies, it is possible that changes in openness may account for increases in aesthetic experience after psychedelic use.suggested that openness to experience, although not generally seen as an emotional trait, is a propensity for awe-like experiences that include expanding one's typical ways of thinking about oneself and the world, and this lends itself to deeper aesthetic experiences. Given that the MEQ30, AWE-S, and EDI have been shown to predict a wide variety of psychological changes after psychedelic experiences, we were surprised to find that they were not significantly related to changes in aesthetic experience in the current study. Although the correlation coefficients were generally trending in the hypothesized direction, it seems that other factors, such as perhaps acute changes in visual processing, may be more relevant in predicting changes in aesthetic experience. There are several limitations that should be considered when interpreting the results. First, the study used an open-label design without a placebo control condition. However, as noted by, the field of psychedelic science-and psychiatry more broadly-have yet to come to a consensus on proper blinding procedures, and even when placebo controls have been used, blinding efficacy has typically not been reported. Given the unique and easily identifiable psychoactive effects of psychedelic drugs, it is likely that blinding efficacy has been compromised in most, if not all, "double-blind" studies to date. Researchers are currently experimenting with various study designs and potential active comparator control conditions to improve blinding in psychedelic trials; however, it could also be argued that open-label designs more closely resemble the conditions in which drugs are administered in the real world and increase ecological validity. A further limitation is that participants were recruited from Soltara Healing Center, where attendees receive ayahuasca a variable number of times; however, there was no relationship between number of ayahuasca sessions attended and changes in aesthetic experience (r = -.01, p > .05). Ayahuasca administration was also embedded into a broader retreat context; non-pharmacological factors, such as the retreat amenities (e.g., hiking trails, yoga/meditation classes, etc.) and social relationships developed at the retreat with attendees and staff, could have theoretically contributed to the documented changes. Although, as noted before, changes in aesthetic experience after psychedelic use have been anecdotally reported across a wide variety of settings without these influences. It remains to be seen if there are potential additive or synergistic effects from integrating psychedelics into retreat settings as compared to laboratory, hospital, or recreational (e.g., festivals, art exhibitions, etc.) settings. Future research should explore the role of setting as well as further investigate the degree to which changes in aesthetic experience are maintained over time. Lastly, it is also important to underscore the strengths of our study. The study was adequately powered, had excellent participant retention, included multiple post-acute follow-ups, was high in ecological validity, as well as utilized a validated and multifaceted measure of aesthetic experience. To conclude, the current study demonstrated that participants exhibited increased levels of aesthetic experience for at least one month following ayahuasca use. Future research is needed to address limitations related to blinding, control groups, and non-pharmacological factors relevant to outcomes with ayahuasca and other psychedelics. Nonetheless, the findings reported here validate anecdotal and qualitative reports of changes in aesthetic experience after psychedelic use and provide important groundwork for future study.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (31)

Papers cited by this study that are also in Blossom

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)

20 cited
Long-term effects of psychedelic drugs: A systematic review

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K. et al. · Neuroscience and Biobehavioral Reviews (2020)

253 cited
Psychedelic drugs and perception: a narrative review of the first era of research

Aday, J. S., Bloesch, E. K., Wood, J. R. et al. · Reviews In The Neuroscience (2021)

54 cited
The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

669 cited
The paradoxical psychological effects of lysergic acid diethylamide (LSD)

Carhart-Harris, R. L., Kaelen, M., Bolstridge, M. et al. · Psychological Medicine (2016)

299 cited
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1236 cited
Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits

Domínguez-Clavé, E., Soler, J., Pascual, J. C. et al. · Psychopharmacology (2018)

81 cited
Effects of psilocybin therapy on personality structure

Erritzoe, D., Roseman, L., Nour, M. R. et al. · Acta Psychiatrica Scandinavica (2018)

265 cited
Show all 31 references
Enhancement of Creative Expression and Entoptic Phenomena as After-Effects of Repeated Ayahuasca Ceremonies

Frecska, E., Móré, C. E., Vargha, A. et al. · Journal of Psychoactive Drugs (2012)

88 cited
180 cited
From Egoism to Ecoism: Psychedelics Increase Nature Relatedness in a State-Mediated and Context-Dependent Manner

Kettner, H., Gandy, S., Haijen, E. C. H. M. et al. · International Journal of Environmental Research and Public Health (2019)

157 cited
Experiences of Encounters with Ayahuasca - “the Vine of the Soul”

Kjellgren, A., Eriksson, A., Norlander, T. · Journal of Psychoactive Drugs (2009)

97 cited
Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review

Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)

287 cited
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)

904 cited
Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin

MacLean, K. A., Leoutsakos, J. S., Johnson, M. W. et al. · Journal for the Scientific Study of Religion (2012)

411 cited
189 cited
Blinding and Expectancy Confounds in Psychedelic Randomised Controlled Trials

Muthukumaraswamy, S., Forsyth, B., Lumley, T. · Expert Review of Clinical Pharmacology (2021)

14 cited
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

283 cited
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)

Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)

475 cited
Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Osório, F. L., Sanches, R. F., Macedo, L. et al. · brazilian Journal of Psychiatry (2015)

483 cited
301 cited
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Neil, J. C., Nutt, D. J. · Journal of Psychopharmacology (2022)

315 cited
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies

Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)

528 cited
Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada

Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)

323 cited

Cited By (2)

Papers in Blossom that reference this study

Acute effects of psilocybin on the dynamics of gaze fixations during visual aesthetic perception

Muller, S., Cavanna, F., de la Fuente, L. A. et al. · Scientific Reports (2025)

2 cited
Increases in Aesthetic Experience Following... — Research Summary & Context | Blossom